GSK plc (GSK) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $51.11, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial... Read more
Hold if already holding. Not a fresh buy at $51.11, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5. Chart setup: RSI 50 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Score 5.5/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — GSK plc
Latest news
- NEWS A Look at GSK PLC (GSK) After 5.6% Decline -- GF Value $43.80 vs Price $51.40 - GuruFocus — GuruFocus negative
- NEWS GSK plc Stock (GSK) Moved Down by 5.22% on Apr 29: Drivers Behind the Movement - TradingKey — TradingKey negative
- NEWS GSK slides Wednesday, underperforms market - MarketWatch — MarketWatch negative
- NEWS GSK slides after Q1 update as investors focus on outlook, FX headwinds, and one-off vaccine strength - Quiver Quantitati — Quiver Quantitative negative
- NEWS GSK (GSK) Stock Drops 3% Despite Q1 Beat: Legal Provisions Cloud the Picture - MEXC — MEXC positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $51.11, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5. Chart setup: RSI 50 mid-range, Bollinger mid-band. Maintain position. Not compelling to add more. Target $51.07 (-0.1%), stop $49.33 (−3.6%), A.R:R -0.3:1. Score 5.5/10, moderate confidence.
Take-profit target: $51.07 (-0.1% upside). Target $51.07 (-0.1%), stop $49.33 (−3.6%), A.R:R -0.3:1. Stop-loss: $49.33.
Analyst target reached - limited upside remaining; Leverage penalty (D/E 1.1): -0.5; Weak growth.
GSK plc trades at a P/E of 13.4 (forward 9.7). TrendMatrix value score: 5.1/10. Verdict: Hold.
32 analysts cover GSK with a consensus score of 3.5/5. Average price target: $58.
What does GSK plc do?GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty...
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.